

20 August 2025

Treatment of Renal Cell Carcinoma

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage) :

- Avelumab + Axitinib <5
- Axitinib <5
- Cabozantinib 35
- Everolimus <5
- Lenvatinib + Everolimus 9
- Lenvatinib + Pembrolizumab 10
- Nivolumab monotherapy 7
- Nivolumab + Cabozantinib 21
- Nivolumab + Ipilimumab <5
- Pazopanib <5
- Pembrolizumab monotherapy 26
- Pembrolizumab + Axitinib <5
- Radiotherapy only <5
- Sunitinib <5
- Temsirolimus <5
- Tivozanib 19
- Other active systemic anti-cancer therapy <5
- Palliative care only - This information is not available

Q2. In the past three months, how many advanced renal cell carcinoma patients received the following first-line treatments?

- Avelumab + Axitinib (Bavencio + Inlyta)
- Cabozantinib (Cometriq)
- Nivolumab (Opdivo)
- Nivolumab + Cabozantinib (Opdivo + Cometriq)
- Nivolumab + Ipilimumab (Opdivo + Yervoy)
- Lenvatinib + Pembrolizumab + (Kisplyx + Keytruda)

This information is not available

20 August 2025

Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for Renal Cell Carcinoma?

- Nivolumab (monotherapy) <5
- Nivolumab + Ipilimumab <5
- Nivolumab + Cabozantinib <5
- Avelumab + Axitinib <5
- Lenvatinib + Pembrolizumab + (Kisplyx + Keytruda) <5

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q4. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)

Nephrectomy

| Month | Full | Partial |
|--------------|-------------|----------------|
| Mar | 8 | 6 |
| Apr | 7 | 7 |
| May | <5 | 9 |
| Jun | 5 | 13 |
| Jul | 6 | 7 |

Q5. Does you trust participate in any clinical trials for the treatment of renal cell carcinoma? If so, please provide the name of each trial and number of patients that are taking part?

We have one trial open that renal cell carcinoma patients are eligible for:

The ModiFY Study: A phase 1/2, multicentre, open-label study of Modi-1 in patients with breast, head and neck, ovarian, or renal cancer

Currently <5 patients recruited.